A few studies investigated the frequency of circulating CD8+ CD161high T cells in MS subjects, with contradictory results in relapsing-remitting MS or pooled cohorts of MS patients with different disease courses (9, 23–25). This evidence concerns the gene CD8A and myeloid sarcoma.